Publications by authors named "Tatiana Piller"
Article Synopsis
- Mab is a highly resistant pathogen that presents a serious threat to individuals with cystic fibrosis and other chronic lung diseases, comparable to multidrug-resistant tuberculosis.
- Current treatment options involve long multidrug therapies, which are often ineffective, leading to high rates of treatment failure and mortality, highlighting the urgent need for new drug development.
- The research focuses on creating stable double-reporter strains of Mab to streamline drug screening, allowing for efficient identification of potential treatments through high-throughput methods while maintaining the pathogen's original characteristics.
Mycothiol (MSH), the major cellular thiol in (Mtb), plays an essential role in the resistance of Mtb to various antibiotics and oxidative stresses. MshC catalyzes the ATP-dependent ligation of 1--(2-amino-2-deoxy-α-d-glucopyranosyl)-d--inositol (GlcN-Ins) with l-cysteine (l-Cys) to form l-Cys-GlcN-Ins, the penultimate step in MSH biosynthesis. The inhibition of MshC is lethal to Mtb.
View Article and Find Full Text PDFTuberculosis (TB) still has a major impact on public health. In order to efficiently eradicate this life-threatening disease, the exploration of novel anti-TB drugs is of paramount importance. As part of our program to design new 2-azaanthraquinones with anti-mycobacterial activity, various "out-of-plane" tetrahydro- and octahydrobenzo[j]phenanthridinediones were synthesized.
View Article and Find Full Text PDFThe ever-increasing incidence of drug-resistant infections has invigorated the focus on the discovery and development of novel treatment options. The discovery and investigation of essential mycobacterial targets is of utmost importance. In addition to the discovery of novel targets, focusing on non-lethal pathways and the use of host-directed therapies has gained interest.
View Article and Find Full Text PDF